Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Brukinsa showed a higher overall response rate (97.5%) compared to Rituxan (88.7%), highlighting its superior efficacy in treating CLL/SLL. Brukinsa demonstrated consistent PFS benefits regardless of ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

“This is the first combination of a BTK inhibitor plus a BCL-2 inhibitor that we expect will receive FDA approval in the U.S, ...